Navigation Links
VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Date:11/17/2009

MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time.

Conference Call Information

Domestic callers: 1-800-776-0853

International callers: 1-913-312-0980

Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                Investor Relations:  The Trout Group
    Timothy E. Morris                               Brian Korb
    Chief Financial Officer                         646-378-2923
    650-934-5200

                                  Media Relations:  Pure Communications, Inc.
                                                    Dan Budwick
                                                    973-271-6085

SOURCE VIVUS, Inc.


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun ... feet to its Welch Allyn campus. ... bring more than 100 new jobs to ... maintained a significant presence for more than 100 years. ... a large portion of which will be R&D and ...
(Date:5/4/2017)... CAESAREA, Israel , May 4, 2017  DarioHealth ... with mobile health and big data solutions, today announced ... an A&D Company, and STI Technologies Limited to lower ... effective immediately. Through STI,s innoviCares card, which is available ... , DarioHealth customers will be eligible for additional ...
(Date:5/3/2017)... 2017  Getinge, a leading global provider of ... and cost efficiency within healthcare and life sciences, ... practice demonstrating that intra-aortic balloon counterpulsation (IABC) appears ... patients. The single-center, retrospective, observational study showed that ... ® 50cc intra-aortic balloon (IAB) in contemporary ...
Breaking Medicine Technology:
(Date:5/24/2017)... Cincinnati, OH (PRWEB) , ... May 24, 2017 , ... ... discreet and comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal ... is why she offers convenient, clear braces in Cincinnati, OH. Patients no longer need ...
(Date:5/24/2017)... Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which the ... on the pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Rob Lowe is ... “Informed,” developed for Public Television. “Informed” brings the public important topics from all aspects ... treatment of the feet and issues surrounding feet and ankles. , Podiatry is essential ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and Clinical Integration company, announced today that its iClinic V12.2 solution has achieved ... Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize team-based care with ...
(Date:5/23/2017)... ... 2017 , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations ... Rory Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s ... ) today reported on a new study released on May 21, 2017 in the ...
Breaking Medicine News(10 mins):